Substituted (+)-6-hydroxy-morphinan derivatives for stereoselective microglial inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroinflammatory diseases and opiate dependence lack effective, stereoselective inhibition of microglial activation, with existing mu opiate receptor antagonists like naloxone and naltrexone exhibiting non-stereoselective inhibition.
Innovation Solution
Development of substituted (+)-6-hydroxy-morphinans and (+)-6-amine-morphinans that preferentially bind to microglia in the central nervous system, inhibiting their activation, with specific compounds like (+)-nalbuphine and (+)-nalfurafine being used to achieve this inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mu opiate receptor antagonists like naloxone and naltrexone are used to inhibit microglial activation, then microglial activation is inhibited, but the inhibition is non-stereoselective and lacks enhanced activity
Solution Approach 1:
The patent applies asymmetry by developing compounds with specific stereochemistry - exclusively the (+) enantiomers of 6-hydroxy-morphinan and 6-amino-morphinan structures. This chiral specificity enables stereoselective binding to microglial targets, distinguishing the invention from prior non-stereoselective antagonists like naloxone and naltrexone.
Solution Approach 2:
The patent introduces local quality modifications by substituting specific positions on the morphinan ring structure (particularly position 6 with hydroxy or amino groups). These localized structural changes enhance microglial inhibitory activity while maintaining stereoselectivity, allowing the compound to interact specifically with microglial receptors.
2Reliability
If substituted morphinan compounds are developed to enhance microglial inhibitory activity, then activity is enhanced, but compound complexity increases
Solution Approach 1:
The patent employs local quality by introducing substitutions at specific positions (particularly position 6) of the morphinan ring rather than modifying the entire structure. This targeted approach enhances microglial inhibitory activity while minimizing overall structural complexity compared to complete structural redesigns.
Data Source
AI summary
The present invention provides (+)-morphinanium compounds comprising substituted 6-hydroxy or 6-amine groups. The invention also provides methods for inhibiting microglial activation by administering the compounds of the invention.